PDCD1 and hepatocellular carcinoma: To our knowledge, this is the first study to report the role of 18F-FDG PET in predicting pathological response and prognosis of unresectable HCC patients after treated by Lenvatinib in combination with PD-1 inhibitors as conversion therapy.